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Rhubarb is commonly used as a cathartic in Asian countries. However, researchers have devotedextensive 
concerns to the quality control and safety of rhubarb and traditional Chinese preparations composed 
of rhubarb due to the instable purgative effect and potential nephrotoxicity of anthraquinones. In this 
study, we aimed to prepare rhubarb total free anthraquinones (RTFA) oral colon-specific drug delivery 
granules (RTFA-OCDD-GN) to delivery anthraquinones to colon to produce purgative effect. RTFA-
OCDD-GN were prepared using chitosan and Eudragit S100 through a double-layer coating process and 
the formulation was optimized. Continuous release studies were performed in a simulated gastric fluid 
(pH 1.2), followed by a small-intestinal fluid (pH 6.8) and a colonic fluid (pH 7.4, containing rat cecal 
contents). The purgative effect test was performed in rats. The dissolution profile of RTFA-OCDD-GN 
showed that the accumulative dissolution rate of RTFA was about 83.0% in the simulated colonic fluid 
containing rat cecal contents and only about 9.0% in the simulated gastrointestinal fluids. And the RTFA-
OCDD-GN could produce the comparative purgative activity as rhubarb, suggesting it could deliver the 
free AQs to the colon. The RTFA-OCDD-GN was a useful media to enhance the purgative activity of 
free anthraquinones after administered orally.
Keywords: Rhubarb. Anthraquinones. Oral colon-specific drug delivery granules. Dissolution. Purgative 
activity.
INTRODUCTION
Rhubarb, a well-known Chinese herbal medicine, 
has been widely used for thousands of years in China due 
to its purgative activity (Fu et al., 2011). As one of main 
active constituents of rhubarb, anthraquinones (AQs) are 
usually considered as the chemical basis of purgative 
activity of rhubarb. AQs exist both in free and conjugated 
forms, and the most is conjugated AQs in rhubarb medical 
material (RMM). Free AQs consisted of aloe-emodin, 
rhein, emodin, chrysophanol and physcione. Conjugated 
AQs are glucoside of free AQs with a β-glucosidic bond 
(Fu et al., 2011; Wang, 1991; Yi et al., 2011) (the chemical 
structure of AQs was shown in Scheme 1). The conjugated 
AQs, which bear β-glucosidic bonds, can avoid being 
hydrolyzed by α-glucosidase in the upper GI tract, then 
reach colon and be hydrolyzed to free AQs by bacteria-
producing β- glucosidase stimulating purgation (Wu, 
2002; Min et al., 2008; Yang, Wang, Zhang, 2012). Hence 
the free AQs are the ultimate substance playing such a 
purgative action as demonstrated in the previous studies 
(Wu, 2002; Yamauchi et al., 1992). The mechanism of 
purgative activity produced by free AQs is to stimulate 
large intestinal paries and nervous plexus to promote 
intestinal peristalsis and reduce water absorption at colon 
(Rauwald, 1998; Yang et al., 2011). However, free AQs 
can be rarely delivered to colon due to the absorption or 
destruction in upper gastrointestinal (GI) tract after oral 
administration. Hence the rhubarb containing conjugated 
AQs is used to exert purgative effect in clinic. 
Chinese Pharmacopoeia records a total of 104 types 
of rhubarb-containing traditional Chinese medicines 
(TCM). In these TCM, rhubarb exerts the main purgative 
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activity. However, conjugated AQs are easily hydrolyzed 
to free AQs in the process of extracting rhubarb, which 
resulted in the attenuation of purgative activity of rhubarb 
free AQs extract (Wu, 2002; Sun et al., 2006). Therefore, 
the rhubarb used in the TCM is in the form of either 
all or partial crude powder. Due to the difference on 
field, cultivation and harvesting time, rhubarb and these 
rhubarb-containing TCM exhibited instable purgative 
effect. Such as San-Huang tablet (SHT), it contains 
rhubarb and has been used popularly to treat constipation 
in clinic. However, it exhibited some defects, such as 
large oral dosage, instable purgative effect and so on. To 
overcome these problems, San-Huang dispersible tablet 
(SHDT) is successfully prepared in our previous study. In 
the formulation of SHDT, rhubarb total free AQs (RTFA) 
extract is used instead of rhubarb crude power and rough 
extract, and then is granulated by the enteric polymer. 
The pharmacodynamic study results indicated that SHDT 
exerted strong and stable purgative effect compared with 
SHT (Liu et al., 2009). 
In recent years, more and more studies have 
reported that emodin and other AQs can induce renal 
toxicity after oral administration (Keiyu et al., 2011; 
National Toxicology Program, 2001). These studies have 
promoted researchers to think about the safety of rhubarb 
and the preparations containing rhubarb. Interestingly, 
the nephrotoxicity caused by processed rhubarb was 
attenuated in comparison with rhubarb due to the reduction 
of conjugated AQs in the processed rhubarb (Wang et al., 
2009). Moreover, the in situ enteric absorption kinetics 
of free AQs demonstrated that most of free AQs were 
absorbed in the small intestinal and only a little part 
were absorbed in colon (Liu et al., 2011). Therefore, 
we presented a hypothesis that RTFA extract is used as 
the alternative of rhubarb and the almost all free AQs 
contained in the RTFA extract is delivered to colon that 
can contribute to improve the purgative effect and reduce 
the nephrotoxicity. 
Colon-specific drug delivery system (OCDDS) 
can prevent drug from being absorbed in the upper GI 
region and then promptly release into the proximal 
colon (Italia et al., 2007; Klan, Prebeg, Kurjakovic, 
1999; Piao, Lee, Lee, 2008). Various approaches have 
been used for oral delivery of drug to the colon, which 
include time-dependent system, pH-dependent system 
and bacteria-dependent delivery. However, the OCDDS 
with single transmit system has some defects, such 
as being easily effected by food and GI tract pH and 
movement, further leading to the release profiles with 
a poor reproducibility (Ashford et al., 1993; Moore, 
Flanner, 1996). Thus the combination of two principles 
is usually proposed to obtain satisfactory OCDDS. Many 
studies have demonstrated that chitosan can be used as 
the carrier to prepare OCDDS due to its low toxicity, 
good biocompatibility and biodegradability (Tozaki et 
al., 1997; Tozaki et al., 2002). However, chitosan can be 
dissolved in acidic solution. Therefore, an outer enteric 
coating is essential to prevent the early breakdown of 
OCDDS prepared with chitosan in the stomach (Khan, 
Prebeg, Kurjakovic, 1999). Eudragit S100 and Eudragit 
L100 are dissolved in aqueous medium above pH 6.8, 
hence the polymers are commonly used as the carriers 
to prepare the pH-dependent OCDDS (Kaur, Kim, 
2009). So this paper aimed to prepare RTFA oral colon-
specific drug delivery granules (RTFA-OCDD-GN) 
using chitosan and pH-dependent Eudragit polymers 
as carriers by a double-layer coating process to deliver 
the free AQs contained in the RTFA extract to colon 
releasing. Moreover, in vitro dissolution of this newly 
developed drug delivery system were studied, and the in 
vivo purgative activity was compared with RMM. 
MATERIAL AND METHODS
Materials
Dried root and rhizoma of Rheum officinale 
Baill. of the Polygonaceae family were purchased from 
Beijing TongRenTang Drugstore and identified by 
Professor Chunying Zhao, a botanist at Chengde Medical 
College (Hebei, China). Methacrylic acid copolymers 
(Eudragit S100) and Eudragit L100 were purchased from 
Changwei Medicine Corporation (Shanghai, China), and 
SCHEME 1 - Chemical structures of AQs and AQs glycosides.
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polyethylene glycol-6000 (PEG-6000) was purchased 
from Zhengxing Chemical Industry Research Institute 
(Suzhou, china). Chitosan (viscosity of 100 cps) was 
purchased from Fuchen Chemical Industry Company 
(Tianjin, China). Hydroxypropyl methyl cellulose 
(HPMC) and microcrystalline cellulose (MCC) were 
purchased from Zhanwang Medicine Limited Company 
(Huzhou, China). Glycerinum and diethyl phthalate 
(DEP) and castor oil and lauryl sodium sulfate (SDS) 
was obtained from Jiaxing Chemical Industry Co., Ltd. 
(Tianjin, China). Methyl alcohol of chromatogram grade 
was purchased from Xiehehaopeng Chromatogram 
Science & Technology Co., Ltd. (Tianjin, China). Other 
chemicals and solvents were of analytical reagent grade, 
and double-distilled water was used throughout the 
study.
Animals
Sprague Dawley (SD) rats weighing 180-240 g were 
provided by Tianjin Shanchuanhong Laboratory Animal 
Science & Technology Co., Ltd. (License No. SCXK 
2009-0001). All animal experiments were performed 
in accordance with the Guide for the Care and Use of 
Laboratory Animals, as adopted and promulgated by the 
Ministry of Science and Technology of China.
Extraction of rhubarb
The rhubarb was extracted according to the method 
(Li et al. (2009)). Briefly, rhubarb was extracted by 
30% ethyl alcohol three times and then the filtrate was 
concentrated under vacuum. The concentrated liquid was 
added in the column of anion exchange resin and eluted. 
Then the eluant was collected, concentrated and filtered. 
The filtrate was dried in oven at 40°C. The dried residue 
was the RTFA extract, in which the AQs existed only in 
free form and the content of RTFA determined by HPLC 
(Liu et al., 2005) was 54.5%.
Core drug-loaded granules preparation
RTFA extract (smaller than 150 µm) was mixed 
with PEG-6000 and MCC (smaller than 150 µm) (1:0.6:4, 
w:w:w). Then the mixture was granulated using 9 mL of 
aqueous solution containing 2% (w:v) HPMC and 2% 
(w:v) PEG-6000 as adhesive with high-speed stirring 
machine (Song Qing Machinery Factory, China). The 
granules were oven-dried at 50°C and screened through 
a 50-mesh sieve to obtain core drug-loaded granules. 
The formulation was screened with the accumulative 
dissolution rate of RTFA in pH 7.4 medium as an index 
and the optimized formulation of core drug-loaded granule 
was listed in Table I. 
Granule coating
Chitosan subcoating
Firstly, chitosan was dissolved in 1% HCl aqueous 
solution (Orienti et al., 2002) at a concentration of 1.20% 
(w:v) and stirred overnight prior to coating. Then, glycerin, 
as the plasticizer of chitosan subcoating formulation, 
equal to 20% weight of the dry polymer, was added in 
the chitosan solution stirring for 1h to prepare the sub-
coating fluid. The subcoating formulation was listed in 
Table II. One hundred gram of core drug-loaded granules 
were coated with 420 mL chitosan sub-coating fluid by 
a fluid bed coating apparatus equipped with a bottom 
sprayer. Briefly, the coating process was performed using 
following parameters: inlet temperature of 80 °C, product 
temperature of 55°C, spray rate of 1.0-1.6 rpm, atomizing 
air pressure of 0.08-0.1 MPa and nozzle diameter of 0.5 
mm. The subcoating granules were further fluidized for 
20 min and oven-dried at 40°C for 2 h. The chitosan 
subcoating formulation was screened with the dissolution 
profile of sub-coating granule in simulated small intestinal 
fluid for 4 h. 
Eudragit S100 coating
Firstly Eudragit S100 was dissolved in 95% 
ethanol aqueous solution, and then the polymer solution 
TABLE I - The formulation of core drug-loaded granules
Ingredient Amount (g, mL)
RTFA extract (the content of 
RTFA is 54.5%)
17.9
MCC 71.6
PEG-6000 10.5
2% (w/v) aqueous solvent of 
HPMC and PEG-6000
32
Core drug-loaded granules 100
TABLE II - Chitosan subcoating formulation
Ingredient Amount (g, mL)
chitosan 1.25
glycerin 0.312
1% hydrochloric aqueous 
solution 100
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was mixed with DEP (equal to 20% weight of the dry 
polymer) and 3% (w/v) of talcum, and finally the mixture 
was stirred for 24 h to obtain the uniform Eudragit S100 
coating fluid. The Eudragit S100 coating formulation 
was listed in Table III. In the formulation, DEP was 
used as the plasticizer and talcum was used as anti-
sticking agent. Subsequently, the 100 g of sub-coating 
granules were coated with 350 mL Eudragit S100 
coating fluid. The coating process was performed using 
following parameters: inlet temperature of 50°C, product 
temperature of 40°C, spray rate of 1.2-2.0 rpm, atomizing 
air pressure of 0.05-0.07 MPa and nozzle diameter of 0.5 
mm. Double-layer coated granules were further fluidized 
for 20 min, oven-dried at 40°C for 2 h and then sieved at 
40-60 mesh. The double layer coating granules obtained 
was RTFA-OCDD-GN. The content of RTFA determined 
by HPLC (Liu et al., 2005) was 8.49% in RTFA-OCDD-
GN. The Eudragit S100 coating formula was screened by 
the accumulative dissolution rate of RTFA in simulated 
stomach and small intestinal fluid.
Factorial design
According to the results of signal factor, the 
dissolution profile of RTFA-OCDD-GN was affected 
by the amount of chitosan formulation and Eudragit 
S100 formulation respectively. The factorial design 
was constructed by statistical software (SPSS. 19.0) to 
investigate the interaction of factor A (the amount of 
chitosan formulation) and factor B (the amount of Eudragit 
S100). The data was analyzed using the variance index L 
which is calculated by the weighted grading method with 
the equation as following:
 (1)
In the equation (1), the L1 expressed the dissolution 
rate in the simulated gastric and small intestinal fluid (the 
weight was 1), the L2 expressed the dissolution rate in the 
simulated colonic fluid (the weight was 2). The factor 
levels were presented in Table IV. Nine experimental runs 
were formulated for RTFA-OCDD-GN.
The reproducibility of optimized formulation
Three batches RTFA-OCDD-GN were prepared 
with the optimized formulation. The reproducibility was 
evaluated using the method of similarity factor, with the 
accumulative dissolution rates of RTFA in the simulated 
gastric, small intestinal and colonic fluid as indexes. The 
similarity factor (f2), a method recommended by FDA, 
can be used to evaluate the comparability among different 
batches of preparations objectively. The f2 is calculated 
with the equation (2) as following:
 (2)
In the equation (2), YRt and YTt expressed the 
accumulative dissolution rate at different time of reference 
and test preparation respectively; the n expressed the 
numbers of withdrawing samples. The FDA provides that 
the two dissolution curves is completely coincident when 
f2 is equal to 100, similar when f2 is between 50 to 100 and 
not similar when f2 is below 50. 
The reference dissolution curve of RTFA-OCDD-
GN was defined in the paper as following: the accumulative 
dissolution rate of RTFA in the simulated gastric fluid for 
2h was approximate 0%, and it was below 10% in the 
simulated small intestinal fluid for 4h, and it was more 
than 80% in the simulated colonic fluid for 4h.
Dissolution test
The dissolution test was performed in triplicate 
using dissolution apparatus (Tian Da Tian Fa Science 
& Technology Co., Ltd., Tianjin, China) at 37°C with 
a stirring speed of 75 rpm according to the Chinese 
Pharmacopoeia method with some minor modifications. To 
simulate the various pH of GI tract in vivo, the continuous 
pH gradient solutions were used as dissolution medium. 
Firstly RTFA-OCDD-GN and RTFA extract, containing 
6.0 mg of RTFA, were placed in 900 mL of simulated 
gastric fluid (pH 1.2, containing 0.4% SDS) for 2 h, and 
then placed in 900 mL of simulated small-intestinal fluid 
(pH 6.8, containing 0.4% SDS) for 4 h, finally placed in 
100 mL of simulated colonic fluid (pH 7.4, containing rat 
cecal contents and 0.4% SDS) for 4 h with continuous 
nitrogen gas supply. 2 mL samples were withdrawn at 
the given time intervals and immediately filtered through 
a 0.22-μm membrane. The initial filtrate was discarded. 
Meanwhile an equal volume of prewamed medium was 
added. The RTFA concentration in each filtered sample 
was determined using HPLC. 
TABLE III - Enteric coating formulation
Ingredient Amount (g, mL)
Eudragit® S100 5
DEP 1
talc 3
95% ethanol solution 100
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As demonstrated in the literature (Englyst, Hay, 
Macfarlane, 1987; Yang, Chu, Fix, 2002; Li et al., 
2003), chitosan was degraded by the rat cecal contents 
because there is some microflora in the rat cedal contents 
generating β-glycosidase. Thus the pH 7.4 phosphate 
buffer containing rat cecal contents was used to simulate 
the colonic fluid in this study. The rat cecal contents 
were obtained as following. In order to activate the 
β-glycosidase, five SD rats weighing 200-300 g were 
intragastrically administered with 2 mL chitosan solution 
(2%, w/v) daily for 7 days. Rats were sacrificed by 
intraperitoneal injection with excessive ethyl carbamate 
at 30 min before the drug release study. The caecum was 
removed from the abdomen, and both ends were ligated, 
cut and weighed using the weight-bearing method. Then 
the cecal contents were suspended in 5% (w/w) bicarbonate 
buffer solution (NaHCO3 9.240 g, Na2HPO3 7.125 g, NaCl 
0.47 g, KCl 0.45 g, CaCl2 0.073 g and MgCl2 0.087 g were 
dissolved in 1,000 mL distilled water) previously bubbled 
with nitrogen gas. All these reactions were performed 
under nitrogen atmosphere. The activity of β-glycosidase 
contained in the rat cecal contents was verified by the 
dissolution test of core drug-load granules and granules 
sub-coated by chitosan in the pH 7.4 phosphate buffer with 
the presence or absence of rat cecal contents (Figure 1).
Pharmacodynamic study
RMM sample preparation
RMM was powdered and then extracted with 
eight volumes of 40% ethanol for three times below 
40°C; the filtrates were pooled, concentrated and then 
freeze-dried and stored at 4°C until further analysis. 
This dried extract was used as the RMM samples. The 
contents of total AQs, free AQs and conjugated AQs 
determined by the method described in the Chinese 
Pharmacopoeia (Pharmacopoeia, 2010) were 9.8%, 4.8% 
and 5.0% respectively. The ratio of conjugated AQs and 
free AQs in the extract was proximal 1:1 (w:w), which 
was consistent with that of RMM containing. The RMM 
samples were suspended with 0.5% CMC-Na before the 
oral administration.
Purgative activity test
A total of 70 healthy SD rats weighing 180-200 
g were housed in a constant temperature environment 
(21°C) with a 12-h light/dark cycle. A standard diet with 
water was supplied during the period of acclimatization 
for 1 week. The rats were fasted for a night prior to the 
experiment. The rats were randomLy divided into seven 
groups with five males and five females in each group. The 
seven groups were administered orally RTFA-OCDD-GN 
(low-, medium- and high- dosage), RMM samples (low-, 
medium-, high- dosage) and normal saline, respectively. 
As demonstrated in the previous study, the RTFA contained 
in RMM samples barely produced purgative effect. Thus in 
the study the dosage of RTFA contained in RTFA-OCDD-
GN was equal to that of total conjugated AQs contained in 
RMM samples. The low-, medium- and high- dosage of 
orally administered RMM samples was 0.66, 0.33, 0.165 
g/kg (equivalent to total conjugated AQs as 0.03056, 
0.01528, 0.00764 g/kg) respectively, and those of RTFA-
OCDD-GN was 0.36, 0.18, 0.09 g/kg (equivalent to RTFA 
as 0.03056, 0.01528, 0.00764 g/kg) respectively. The 
control group was orally administered with normal saline. 
The rats in seven groups were continuously monitored 
for 8 h immediately after the intragastric administration 
to obtain the defecation frequency and the conditions of 
stools. The conditions of stools were divided into five 
types as followings: normal, soft, loose, semi-liquid and 
watery. The diarrhea was evaluated with the defecation 
frequency of non-normal defecation.
FIGURE 1 - The dissolution profiles of core drug-loaded granules and granules subcoated by chitosan in pH 7.4 with the obsence 
of rat cecal contents (A) and presence of rat cecal contents (B).
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Analytical method
HPLC method was used to evaluate the dissolution 
rate of AQs from the different formulations. The HPLC 
analysis was conducted using Agilent 1200 (Agilent, 
USA). The separation was carried out on a reversed-phase 
Diamonsil C18 chromatographic column (250 mm × 4.6 
mm, 5 μm); the mobile phase was methanol and 1.1% 
perchloric acid aqueous solution (80:20, v:v); the flow rate 
was set at 1 mL/min; the wavelength was 254 nm; and the 
column temperature was maintained at 30°C. The standard 
curves of five free AQs were linear (r>0.999) over the 
concentration range of 0.06624-6.624, 0.17933-17.933, 
0.05088-5.088, 0.04378-4.378 and 0.02016-2.016 μg/
mL, respectively. The inter-day and intra-day precisions 
were below 1.0%. The average recovery was 99.5% with 
RSD of 1.4%.
Statistical analysis
All values are expressed as the mean ± standard 
deviation (SD). Significant differences between groups 
were analyzed by one-way ANOVA (SPSS 19.0 software). 
A P value of less than 0.05 was considered as statistically 
significant. 
RESULTS AND DISCUSSION
Formulation Optimization
Core drug-loaded formulation
The effect on the dissolution profile of different 
core drug-loaded formulations (F 1, F 2 and F 3) was 
shown in Figure 2. In F 1, F 2 and F 3, the ratio of RTFA, 
MCC and PEG 6000 was 1:2:0.6, 1:4:0.6 and 1:4:1.2 
(w:w:w), respectively. As shown in Figure 2A, in the 
pH 7.4 phosphate buffer the accumulative dissolution 
rate of RTFA from the core drug-loaded granules was 
80.40%, 82.94% and 81.40%, respectively. This result 
showed that the ratio of RTFA, MCC and PEG screened 
in the formula had no significant effect on the dissolution 
rate of RTFA in the simulated colonic fluid. However, 
the core granules prepared by F 1 had a high viscosity, 
which was not advantageous for the following membrane 
coating process. In addition the drug loading in F 2 was 
superior to that of F 3. Thus the ratio of RTFA, MCC and 
PEG-6000 was selected as 1:4:0.6. The concentration 
of HPMC, as an adhesive, was optimized. As shown 
in Figure 2B, the dissolution rate of RTFA from the 
core drug-loaded granules prepared with 2% HPMC 
was 82.4%, which was superior to 1% and 3% HPMC. 
Moreover, using 2% HPMC containing 2% PEG6000 as 
adhesive, the dissolution rate was high in comparison with 
2% HPMC. Thus the 2% HPMC containing 2% PEG6000 
was chosen as the adhesive. The Figure 2C showed that 
the dissolution profiles of three-batch core drug-loaded 
granules prepared with the optimized formulation (Table I) 
was fast and continuous with the accumulative release of 
80% within 2 h. 
Sub-coating formulation
As shown in Figure 3, the dissolution profiles of 
sub-coating granules in simulated small intestinal fluid 
for 4h were affected by the concentration of chitosan, 
the type and concentration of plasticizer, the amount 
of sub-coating formulation and the atomizing press. 
The dissolution profiles of the granules subcoated with 
chitosan at the concentration of 1.0%, 1.2% and 1.3% 
showed that the accumulative dissolution rate of RTFA 
were 28.49%, 19.50% and 19.84% in the simulated 
small intestinal fluid for 4h, respectively (Figure 3A). 
These results indicated that the dissolution rate of 
granules subcoated with chitosan of 1.0% was highest 
among three concentrations and the dissolution profiles 
of granules subcoated with chitosan of 1.2% and 1.3% 
showed no significant difference, demonstrating the 
release of RTFA was decreased significantly when the 
chitosan concentration reaching 1.2%. However, the 
coating process of granules subcoated with chitosan at 
the concentration above 1.3% was very hard to achieve 
due to the high viscosity of chitosan. Thus, the chitosan 
concentration was optimized as 1.2% (w:v). In addition 
the accumulative dissolution rate of RTFA from granules 
subcoated with different plasticizers, such as glycerol, 
DEP and castor oil, was 19.35%, 28.82% and 29.86% 
respectively (Figure 3B). And the Figure 3C showed 
that the dissolution rate was reduced effectively with the 
glycerol concentration as 25% and 30%. The glycerol, 
with the concentration of 25%, was used as plasticizer 
in the optimized formulation due to the low viscosity. 
Moreover, when the amount of chitosan coating fluid 
was above 400 mL, it was advantageous to obtain 
a satisfactory release profile (Figure 3D). And the 
Figure 3E showed that the atomizing press could affect 
the dissolution profile of RTFA-OCDD-GN and the 
accumulative dissolution rates of RTFA were 22.9% and 
7.59% and 7.13% when the atomizing press was screened 
as 0.05, 0.08 and 1.0 Mpa, respectively. Thus, the 
parameter of atomizing press was chosen as 0.08 Mpa. 
According to the results above, the optimized chitosan 
sub-coating formulation was summarized as Table II.
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Enteric coating formulation
The ratio and concentration of Eudragit S100 and 
L100, the type and concentration of plasticizer, the amount 
of enteric coating fluid and the atomizing press were 
screened to optimize the enteric coating formulation. The 
dissolution profiles of different formulations in simulated 
gastric fluid (pH 1.2) for 2h and simulated small intestinal 
fluid (pH 6.8) for 4h were shown in Figure 4. The Figure 
4A showed that the accumulative dissolution rate of RTFA 
was significantly affected by the ratio of Eudragit S100 
and L100. The dissolution rate of RTFA was increased 
with the increasing Eudragit L100 in enteric coating 
formulation. The concentration of Eudragit S100 in the 
enteric coating formulation could impact the dissolution 
profile (Figure 4B). When it was 3%, the dissolution 
profile in the simulated gastric fluid was not accepted 
by the criteria documented in Chinese Pharmacopoeia 
for the enteric performance test. However, the release 
profiles showed that there was no drug released in the first 
2 h with the concentration of Eudragit S100 between 5% 
and 6%. These results indicated that Eudragit S100 with 
the concentration above 5% possessed satisfactory film 
forming property and the ability to prevent the release of 
RTFA from the coating granules in the simulated gastric 
fluid. However, the Eudragit S100 concentration in the 
enteric coating formulation was optimized as 5% due 
to the advantage for the coating process by fluid bed. 
Different types of plasticizers have different effects on 
the dissolution profile (Figure 4C). The DEP could reduce 
significantly the dissolution rate of RTFA in comparison 
with PEG6000 and castor oil. Moreover, the dissolution 
profiles of granules coated by enteric coating formulation 
showed no significant difference with the DEP used as 
plasticizer at the concentration of 20% and 25% (w/w) 
(Figure 4D). However, it was found that the granules 
adhered together easily in the coating process when the 
amount of plasticizer in the enteric coating fluid was 
increased up to 25%. Hence the concentration of DEP 
was optimized as 20%. Furthermore, more than 300 mL 
of Eudragit S100 enteric coating formulation and above 
0.05 Mpa atomizing press were optimized to obtain the 
satisfactory dissolution profile (Figure 4E-F). According 
to the results above, the optimized enteric coating 
formulation was summarized as Table III.
FIGURE 2 - The effect on dissolution rate of the ratio of RTFA, MCC and PEG (A) and the concentration of HPMC (B); and the 
release profile of RTFA from the core drug-loaded granules in a simulated colonic fluid (pH 7.4) containing rat caecal contents (C).
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FIGURE 3 - The effect on dissolution rate in a simulated small-intestinal fluid (pH 6.8) of the chitosan concentration (A), the type 
of plasticizers (B), the concentration of plasticizers (C), the amount of coating fluid (D) atomizing press (E).
FIGURE 4 - The effect on dissolution rate in a simulated gastric fluid (pH 1.2) and a simulated small-intestinal fluid (pH 6.8) of 
the ratio of Eudragit S100 and L100 (A), the Eudragit S100 concentration (B), the type of plasticizers (C), the concentration of 
plasticizers (D), the amount of coating fluid (E) atomizing press (F).
The interaction of chitosan formulation and Eudragit 
S100 formulation
According to factorial design of RTFA-OCDD-GN, 
the factor combinations yielded a variety of calculated 
mean L values. The values of L are shown in Table IV. 
The values of L were in the range of 19.42-12.27 for runs 
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1 to 9. The lowest value for L was achieved by run 9. 
However, the variance of L was not significant for runs 
5 to 9. Thus 420mL of chitosan formulation and 340mL 
of Eudragit S100 formulation were chosen in the study 
due to the availability for the coating process. Analysis 
of variance (ANOVA) according to the data of L value 
is shown in Table V. According to ANOVA, all P-values 
listed presented a significant effect of the independent 
factors on L values and the interaction of A and B was 
presented (P<0.05). These results indicated that the 
chitosan formulation and Eudragit S100 formulation 
produced the synergetic effect on the dissolution profile 
of RTFA-OCDD-GN, contributing to improve the stability 
and reproducibility of RTFA-OCDD-GN.
In vitro dissolution
In the present study, the dissolution test of RTFA-
OCDD-GN were performed successively in the simulated 
gastric fluid (pH 1.2) for 2 h, and then in the simulated 
small-intestinal fluid (pH 6.8) for 4 h, and finally in the 
simulated colonic fluid (pH 7.4) with or without the 
presence of rat cecal contents for 4 h. The dissolution 
profiles of RTFA-OCDD-GN and RTFA extract was shown 
in Figure 5. As shown in Figure 5A, the accumulative 
dissolution rate of RTFA from RTFA-OCDD-GN was 
9.0% in the simulated gastric and small-intestinal fluid 
for 6h, and it was 82.6% in the simulated colonic fluid 
containing rat cecal contents for 4 h; however it was only 
about 10% in the simulated colonic fluid without the 
presence of rat cecal contents. In addition, the dissolution 
profile of RTFA extract showed that the accumulative 
dissolution rate of RTFA was about 80% in the simulated 
gastric fluid for 2h. Although there were slight RTFA 
released from RTFA-OCDD-GN in the simulated gastric 
and small intestinal fluid, the risk of without releasing any 
drug in the GI tract was attenuated, as found in the study 
of Ashford et al. (1993). Thus, these results indicated that 
the RTFA-OCDD-GN was prepared successfully with 
chitosan and Eudragit S100 by the double-layer coating 
process. Moreover, the RTFA-OCDD-GN achieved the 
objectives of colon-specific delivery system: (ⅰ) prevention 
of premature drug release in the GI tract; and (ⅱ) rapid 
drug release in the colonic fluid. The colon-specific release 
characterization of RTFA-OCDD-GN was attributed to 
the release mechanism of Eudragit S100 and chitosan. 
Eudragit S100, a pH-dependent polymer, can dissolve at 
and above pH 7.0. Chitosan, a weak basic copolymer of 
β-(1, 4)-2-acetamido-2-deoxy-D-glucopyranose and 
2-amino-2-deoxy-D-glucopyranose, undergo the 
hydrolysis of their glycoside bonds in the colon. Hence 
the mechanism that the RTFA released from the RTFA-
OCDD-GN was described in detail as followings: during 
the RTFA transporting in the whole gastrointestinal tract 
the RTFA is scarcely released in the stomach, and slightly 
released in the small intestinal due to the dissolution 
of outer Eudragit S100 coating layer, and finally in the 
colon quickly released due to the degradation of chitosan. 
TABLE IV - Experimental runs and the determined values of L
Formulation NO. The amount of chitosan (mL)
The amount of 
resin (mL) L1 L2 L
1 400 300 13.54 2.94 19.42
2 400 340 11.35 2.96 17.31
3 400 380 6.57 4.31 15.19
4 420 300 7.35 4.00 18.70
5 420 340 6.81 3.00 12.81
6 420 380 6.61 3.00 12.61
7 450 300 8.92 2.99 14.90
8 450 340 6.45 2.97 12.38
9 450 380 6.32 2.97 12.27
The values of L1, L2 and L are expressed as mean.
TABLE V - Variance analysis
Factors SS DF MS F P
Total 190.399 26
A 78.208 2 39.104 6269.656 <0.01
B 94.829 2 47.415 7602.121 <0.01
AB 17.249 4 4.312 691.384 <0.01
Error 0.112 18 0.006
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In addition, the Figure 5B showed the reproducibility 
of dissolution test of three batches RTFA-OCDD-GN. 
As shown in Figure 5B, the dissolution profiles of three 
batches RTFA-OCDD-GN were basically similar with 
the value of f2 as between 50 and 100, indicating the 
preparation process of RTFA-OCDD-GN reproduced well. 
Pharmacodynamic study
In the previous study, it was demonstrated that the 
RTFA in a common dosage scarcely produced purgative 
effect (the data not shown). Moreover the rhubarb used 
in the TCM is in the form of either all or partial crude 
powder. Thus the RTFA-OCDD-GN ability to improve 
the purgative activity was compared with RMM samples. 
The comparison of RTFA-OCDD-GN and RMM samples 
on the defecation frequency and consistence of stool was 
shown in Figure 6. Compared with the control group, 
the defecation frequency was increased significantly in 
the RMM samples group (containing low-, middle- and 
high-dosage subgroups) and RTFA-OCDD-GN group 
(containing low-, middle- and high-dosage subgroups) 
(P<0.05). In addition, there was no significant difference 
observed between the RMM samples group and RTFA-
OCDD-GN group (in all dosages, P>0.05). However, the 
consistence of faeces in RTFA-OCDD-GN groups was 
different from that of RMM samples groups. As shown 
in Figure 6B, the frequency of semi-liquid and watery 
defecation in the RTFA-OCDD-GN groups (medium- and 
high- dosage) was decreased significantly in comparison 
with RMM samples groups (medium- and high- dosage) 
(p<0.05). The reason speculated was that RTFA-OCDD-
GN was prepared with RTFA extract, in which AQs existed 
in free form and thereby the free AQs only produced mild 
purgation. Thus the purgative study results indicated that 
RTFA-OCDD-GN could produce corresponding purgative 
effect in low oral dosage compared with RMM samples, 
contributing to reduce the risk of accumulation for AQs in 
vivo; in addition RTFA-OCDD-GN reduced the incidence 
frequency of diarrhea. Moreover, as demonstrated in 
our previous study the purgative effect caused by RTFA 
extract with the dosage used in this study was significantly 
lower than that of RMM (the data not shown in the paper). 
Therefore, these results also suggested that the RTFA-
OCDD-GN could basically delivery all RTFA to the colon 
to release after directly oral administration. Indeed, the 
pharmacokinetic study of RTFA-OCDD-GN confirmed 
that RTFA-OCDD-GN could prevent RTFA from releasing 
and being adsorbed in the stomach and small intestine 
and delivery RTFA to colon, which has been published in 
another paper (Zhang et al., 2015). 
CONCLUSION
In the present study, we successfully prepared 
the RTFA-OCDD-GN through a double-layer coating 
process using chitosan as an inner layer and Eudragit 
S100 as an outer layer. The accumulative dissolution rate 
of RTFA-OCDD-GN was about 83% in the simulated 
colonic fluid with the presence of rat cecal contents, 
whereas it was about only 9.0% in the simulated gastric 
and small-intestinal fluids. These results indicated that 
FIGURE 5 - The dissolution profiles of the core drug-load granules in pH 1.2 and RTFA-OCDD-GN in a simulated gastric fluid 
(pH 1.2) and a simulated small-intestinal fluid (pH 6.8) and a simulated colonic fluid (pH 7.4) in the presence or absence of rat 
cecal contents (A), and the dissolution test reproducibility of three batches RTFA-OCDD-GN (B).
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FIGURE 6 - The comparison on defecation frequency and consistance of faeces of RMM and RTA-OCDD-GN groups after oral 
administration to rats. The data were expressed as mean ± S.D. (n = 10).* P < 0.05, compared with the normal group; #P<0.05, 
compared with the RTFA-OCDD-GN group.
RTFA-OCDD-GN could release specifically in the colon. 
Moreover the RTFA-OCDD-GN and RMM samples 
could produce corresponding purgative activity, but the 
dosage of RTFA-OCDD-GN was only about half of that 
of RMM samples. Therefore, the RTFA-OCDD-GN could 
be a useful drug delivery system to improve the purgative 
effect and reduce the oral dosage for AQs. 
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